{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:59:01Z","timestamp":1790369941697,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00520-026-11100-3","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:27:02Z","timestamp":1786721222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between opioid use and treatment discontinuation in patients receiving nivolumab: a real-world database study"],"prefix":"10.1007","volume":"34","author":[{"given":"Kentaro","family":"Uejima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakae","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Ooba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"11100_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123\u2013135","journal-title":"N Engl J Med"},{"key":"11100_CR2","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803\u20131813","journal-title":"N Engl J Med"},{"key":"11100_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27\u201340","journal-title":"Lancet"},{"key":"11100_CR4","first-page":"1356","volume":"23","author":"M Stewart","year":"2018","unstructured":"Stewart M, Norden AD, Dreyer N, Henk HJ, Brush DR, Su Z et al (2018) An exploratory analysis of real-world endpoints for assessing outcomes among immunotherapy-treated patients with advanced non-small cell lung cancer. Oncologist 23:1356\u20131363","journal-title":"Oncologist"},{"key":"11100_CR5","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/bph.12492","volume":"171","author":"JW Boland","year":"2014","unstructured":"Boland JW, Pockley AG (2014) Influence of opioids on immune function in patients with cancer pain: from bench to bedside. Br J Pharmacol 171:1347\u20131357","journal-title":"Br J Pharmacol"},{"key":"11100_CR6","doi-asserted-by":"crossref","first-page":"22191","DOI":"10.1038\/srep22191","volume":"6","author":"S Banerjee","year":"2016","unstructured":"Banerjee S, Sindberg GM, Wang F, Meng J, Sharma U, Zhang L et al (2016) Opioid-induced gut microbial dysbiosis in mice. Sci Rep 6:22191","journal-title":"Sci Rep"},{"key":"11100_CR7","first-page":"146","volume":"123","author":"AM Hopkins","year":"2020","unstructured":"Hopkins AM, Kichenadasse G, Karapetis CS, McKinnon RA, Rowland A, Sorich MJ (2020) Concomitant medications and immunotherapy outcomes: a systematic review. Eur J Cancer 123:146\u2013156","journal-title":"Eur J Cancer"},{"key":"11100_CR8","first-page":"799","volume":"12","author":"A Botticelli","year":"2017","unstructured":"Botticelli A, Cirillo A, Scagnoli S, Cerbelli B, Strigari L, Cortesi E et al (2017) The role of opioids in cancer response to immunotherapy. Target Oncol 12:799\u2013803","journal-title":"Target Oncol"},{"key":"11100_CR9","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/annonc\/mdz060","volume":"30","author":"GM Blumenthal","year":"2019","unstructured":"Blumenthal GM, Gong Y, Kehl K, Mishra-Kalyani R, Lu D, Khorana AA et al (2019) Analysis of time to treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials and real-world data. Ann Oncol 30:1146\u20131153","journal-title":"Ann Oncol"},{"key":"11100_CR10","first-page":"1056","volume":"50","author":"K Nagai","year":"2021","unstructured":"Nagai K, Tanaka T, Kodaira N, Takahashi Y, Hiroi S, Murakami Y (2021) Data resource profile: JMDC claims database. Int J Epidemiol 50:1056\u20131061","journal-title":"Int J Epidemiol"},{"key":"11100_CR11","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453\u20131457","journal-title":"Lancet"},{"key":"11100_CR12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S (2008) Immortal time bias in pharmacoepidemiology. Am J Epidemiol 167:492\u2013499","journal-title":"Am J Epidemiol"},{"key":"11100_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B Stat Methodol 34:187\u2013220","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"11100_CR14","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D'Agostino Jr","year":"1998","unstructured":"D\u2019Agostino RB Jr (1998) Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a control group. Stat Med 17:2265\u20132281","journal-title":"Stat Med"},{"key":"11100_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41\u201355","journal-title":"Biometrika"},{"key":"11100_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46:399\u2013424","journal-title":"Multivariate Behav Res"},{"key":"11100_CR17","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083\u20133107","journal-title":"Stat Med"},{"key":"11100_CR18","first-page":"2547","volume":"47","author":"U Dafni","year":"2011","unstructured":"Dafni U (2011) Landmark analysis: response to treatment. Eur J Cancer 47:2547\u20132551","journal-title":"Eur J Cancer"},{"key":"11100_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s11523-025-01164-2","volume":"20","author":"CH Yiu","year":"2025","unstructured":"Yiu CH, Menzies AM, Lu CY (2025) Real-world outcomes of pembrolizumab in advanced melanoma by age and sex: a national population-based study. Target Oncol 20:847\u2013859. https:\/\/doi.org\/10.1007\/s11523-025-01164-2","journal-title":"Target Oncol"},{"key":"11100_CR20","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/jco.2015.33.15_suppl.e13033","volume":"33","author":"HA Robbins","year":"2015","unstructured":"Robbins HA, Kurosky SK, Skafida M, Pfeiffer RM, Engels EA (2015) Confounding by indication in observational studies of cancer treatment outcomes. J Clin Oncol 33:1201\u20131208","journal-title":"J Clin Oncol"},{"key":"11100_CR21","first-page":"715","volume":"55","author":"M Salas","year":"1999","unstructured":"Salas M, Hofman A, Stricker BH (1999) Confounding by indication: an example of variation in the use of epidemiologic terms. Eur J Clin Pharmacol 55:715\u2013719","journal-title":"Eur J Clin Pharmacol"},{"key":"11100_CR22","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jclinepi.2012.05.001","volume":"65","author":"RH Groenwold","year":"2012","unstructured":"Groenwold RH, Nelson DB, Nichol KL, Hoes AW, Hak E (2012) Sensitivity analyses to estimate the potential impact of unmeasured confounding in observational studies. J Clin Epidemiol 65:1144\u20131155","journal-title":"J Clin Epidemiol"},{"key":"11100_CR23","doi-asserted-by":"publisher","first-page":"s9","DOI":"10.1191\/0269216306pm1124oa","volume":"20","author":"P Sacerdote","year":"2006","unstructured":"Sacerdote P (2006) Opioids and the immune system. Palliat Med 20:s9\u2013s15","journal-title":"Palliat Med"},{"key":"11100_CR24","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.3389\/fimmu.2019.02914","volume":"10","author":"S Franchi","year":"2019","unstructured":"Franchi S, Moschetti G, Amodeo G, Sacerdote P (2019) Do all opioid drugs share the same immunomodulatory properties? A review from preclinical to clinical evidence. Front Immunol 10:2914","journal-title":"Front Immunol"},{"key":"11100_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054040","volume":"8","author":"J Meng","year":"2013","unstructured":"Meng J, Yu H, Ma J, Wang J, Banerjee S, Charboneau R et al (2013) Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-dependent manner. PLoS ONE 8:e54040","journal-title":"PLoS ONE"},{"key":"11100_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91\u201397","journal-title":"Science"},{"key":"11100_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359:97\u2013103","journal-title":"Science"},{"key":"11100_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11912-026-01789-0","volume":"28","author":"CH Yiu","year":"2026","unstructured":"Yiu CH, Winardi K, Lu CY (2026) Immunological drug-drug interactions in immune checkpoint inhibitor therapy: mechanisms, clinical evidence, and artificial intelligence. Curr Oncol Rep 28:51","journal-title":"Curr Oncol Rep"},{"key":"11100_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M et al (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24:541\u2013550","journal-title":"Nat Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11100-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11100-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11100-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:02:07Z","timestamp":1790366527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-11100-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["11100"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11100-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of the Nihon University School of Pharmacy determined that ethical review was not required for this study (Approval No. 25\u2013009). The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived because of the retrospective study design and the use of pseudonymized administrative claims data, in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person's data in any form, including individual details, images, or videos.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"854"}}